1. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer 
Steven M Keller, MD, Sudeshna Adak, PhD, Henry Wagner, MD, David H Johnson, MD 
The Annals of Thoracic Surgery 
Volume 70, Issue 2, Pages (August 2000)
DOI: /S (00)

2. Fig 1
One hundred ninety-two surgeons accrued patients to the study. The majority entered only 1 patient.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

3. Fig 2
Survival. Patients who underwent complete MLND survived significantly longer than those patients who underwent SS.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

4. Fig 3
Survival with N1 disease. The median survival of patients with N1 disease was significantly prolonged if they had a complete MLND.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

5. Fig 4
Survival with N2 disease. The survival advantage for patients who had undergone complete MLND was also present for those patients with N2 disease.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

6. Fig 5
Right lung tumors. The improved survival with complete MLND was limited to right lung cancers and was present for both upper and lower lobe tumors.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

7. Fig 6
Left lung tumors. The type of lymph node dissection did not influence the survival of patients with left lung cancers regardless of whether the tumor originated in the upper (log rank test, p = 0.90) or lower lobes (log rank test, p = 0.89).
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

8. Fig 7
Disease-free survival, right lung tumors. Median disease-free survival was significantly prolonged in patients with right lung tumors who underwent complete MLND compared with those who underwent SS.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )